Hereditary Angioedema Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Hereditary Angioedema Therapeutics Market Trends and Insights

Commercial Roll-Out of First-In-Class Oral Kallikrein Inhibitors

BioCryst’s berotralstat (Orladeyo) has normalized once-daily oral prophylaxis, driving USD 437 million in 2024 sales and a further 51% year-over-year uplift in Q1 2025. Young, working-age patients favor the pill format, accelerating switches from injectables; 70% of U.S. hereditary angioedema patients now choose oral prophylaxis. A pending FDA decision on KalVista’s sebetralstat could inaugurate the first oral on-demand option, with Phase 3 data showing symptom relief within 1.61 hours versus 6.72 hours for placebo^{[1]Eric Cromer et al., “Oral Berotralstat for Prophylactic Treatment of Hereditary Angioedema,” nejm.org}. These dynamics are enlarging the hereditary angioedema therapeutics market by capturing previously undertreated segments and broadening geographic reach.

Escalating Use of Subcutaneous C1-INH Self-Administration

CSL Behring’s Haegarda cut attack frequency by 95% in pivotal trials and underpinned a global migration from intravenous replacement to patient-controlled subcutaneous dosing^{[2]CSL Behring, “Haegarda Clinical Overview,” cslbehring.com}. Home programs reduce annual per-patient costs by 11.3% and maintain technical failure rates below 2%. Specialty pharmacies supply 24-hour helplines and nurse coaching, reinforcing adherence and freeing infusion-center capacity. Pediatric cohorts as young as eight years now achieve durable prophylaxis outside hospital settings, reinforcing quality-of-life gains.

Momentum Behind Gene-Silencing & CRISPR One-Shot Cures

Intellia’s NTLA-2002 achieved a 98% mean attack reduction over two years with no serious adverse events, suggesting a potential one-time cure. Ionis’s donidalorsen, an antisense oligonucleotide, delivered 81% attack reduction on monthly dosing. These modalities promise to compress lifetime spending from millions of dollars to a single intervention, yet long-term safety surveillance, manufacturing scale-up, and payer risk-sharing frameworks will dictate commercial timelines.

Rising Orphan-Drug Pricing Power & Payer Acceptance

Annual therapy costs above USD 500,000 are supported by documented 77.0% reductions in attack frequency and 59.5% improvements in quality-of-life metrics. Outcomes-based contracts link reimbursement to measured attack reduction, aligning incentives and sustaining innovation. Fast-track and breakthrough designations streamline FDA review, while Europe’s centralized HTA assessments increasingly recognize the rarity and severity of HAE in value determinations^{[3]U.S. Food and Drug Administration, “Rare Disease Development Programs,” fda.gov}.

High Annual Therapy Cost Pressures Healthcare Budgets

Despite strong clinical value, incremental cost-effectiveness ratios can breach USD 150,000 per QALY, challenging conventional thresholds^{[4]Journal of Managed Care & Specialty Pharmacy, “Economic Burden of Hereditary Angioedema,” jmcp.org}. Real-world evidence places direct medical costs near USD 364,000 and indirect losses at USD 52,500 per patient yearly, straining public payers and limiting coverage in low-income markets. Biosimilar potential is restricted by plasma supply constraints and complex biologics manufacturing.

Limited HAE Expertise Outside Tier-1 Academic Centers

Misdiagnosis and delayed treatment persist, especially in rural areas where general practitioners rarely encounter HAE. Telehealth consultations and regional conferences—such as the 2024 HAEi meeting in Manila with delegates from 25 countries—are extending specialist knowledge but remain early-stage. Infrastructure gaps in diagnostics and cold-chain logistics impede equitable access, prolonging unmet need.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: C1 Esterase Inhibitors Maintain Dominance Amid Kallikrein Innovation

C1 esterase inhibitors generated 60.92% of 2025 revenue, anchoring the hereditary angioedema therapeutics market size at USD 3.57 billion. CSL Behring’s Berinert and Haegarda safeguard this position through reliable efficacy and extensive real-world data. Yet kallikrein inhibitors are scaling faster at a 19.12% CAGR, led by BioCryst’s oral berotralstat, which delivered USD 437 million in 2024 sales. With modular oral, subcutaneous, and long-acting monoclonal formats in late-stage pipelines, kallikrein agents are positioned to capture incremental hereditary angioedema therapeutics market share over the forecast window.

Patient preference is steering capital allocation toward oral compounds and long-interval injectables, pressuring conventional plasma-derived segments. Nonetheless, plasma-free recombinant C1-INH (Ruconest) and supply-diversification strategies protect incumbents against sourcing constraints and infectious-disease risk, sustaining a two-pillar class dynamic through 2030.

By Route of Administration: Subcutaneous Gains Ground as Oral Therapies Accelerate

Subcutaneous products contributed 51.48% of hereditary angioedema therapeutics market share in 2025, equal to USD 3.02 billion, and underscore a decade-long shift toward home dosing. Training completion rates above 98% validate the model, while health-economic studies confirm 11.30% annual savings versus hospital-based intravenous care. Concurrently, oral delivery is expanding at 19.7% CAGR, on track to exceed USD 4.72 billion by 2031, driven by berotralstat and the anticipated approval of sebetralstat.

Intravenous treatments, though declining, remain critical for emergency departments and for patients requiring immediate high-dose intervention. Future pipeline assets targeting granule formulations for children aged 2-11 years will further broaden oral reach, reinforcing patient-centric care trajectories.

By Treatment Type: Long-term Prophylaxis Extends Market Momentum

Long-term prophylaxis accounted for 56.85% of 2025 revenue, anchoring the hereditary angioedema therapeutics market size at USD 3.33 billion. Physicians now favor preventive regimens because real-world studies show 77.00% fewer attacks and 52.00% lower emergency-department utilization versus on-demand approaches. Uptake accelerates as once-daily oral berotralstat and every-four-week subcutaneous lanadelumab remove logistical barriers, pushing prophylaxis prescriptions to half of all treated patients in the United States. At an 17.86% CAGR through 2031, prophylaxis will generate the largest absolute dollar expansion, while gene-editing candidates could eventually compress the segment by converting chronic dosing into one-time therapy.

By Patient Type: Type I Dominance Meets nC1-INH Precision Growth

Type I cases held 78.62% of 2025 revenue, translating to USD 4.61 billion and reflecting clear diagnostic criteria and abundant therapeutic options. The nC1-INH cohort is small but rising at 17.55% CAGR as next-generation sequencing exposes mutations in F12 and other genes previously undetected by standard assays. Off-label success with berotralstat plus emerging antisense agents signals imminent label expansions that could lift nC1-INH share above 10.00% by 2031, injecting fresh volume into the hereditary angioedema therapeutics market.

By Distribution Channel: Hospital Pharmacies Retain Control while Online Platforms Surge

Hospital pharmacies dispensed 45.32% of 2025 global sales, a USD 2.66 billion slice driven by initiation protocols and acute-care inventory requirements. Online and specialty-home platforms are the growth engine, advancing at 18.49% CAGR as secure cold-chain couriers and e-prescription portals streamline monthly refills. Digital channels bundle nurse coaching, adherence tracking, and automatic refill reminders, cutting missed doses by 30.00% and reinforcing payer support. As more patients transition to oral prophylaxis, online share is forecast to overtake hospital channels after 2028, further decentralizing the hereditary angioedema therapeutics market.

Geography Analysis

North America held 79.55% of 2025 revenue, reflecting robust reimbursement, fast-track regulatory designations, and dense specialty-pharmacy infrastructure. More than 1,200 U.S. physicians have adopted berotralstat, and payer alignment on outcomes contracts sustains high adherence. Canada leverages provincial formularies for coverage, while Mexico’s medical-tourism corridors attract regional HAE patients seeking advanced regimens.

Europe displays mature penetration, yet continued product cycling sustains value growth. EMA’s positive opinion on garadacimab and MHRA’s lanadelumab pediatric nod highlight regulatory momentum. France’s early-access program reported 65% clinically meaningful quality-of-life gains at six months, reinforcing payer confidence.

Asia-Pacific is the fastest-growing region at 17.44% CAGR, propelled by Japan’s regulatory clarity, China’s expanding rare-disease catalog, and advocacy-driven awareness. The 2024 Manila HAEi summit showcased collaborative efforts across 25 nations, though diagnostic and reimbursement heterogeneity remain hurdles. Investments in regional plasma fractionation and tele-education platforms are expected to mitigate supply and expertise gaps over time.

Regulatory Landscape

Regulation of hereditary angioedema (HAE) therapeutics is shaped by rare-disease pathways that accelerate review and provide commercial incentives. Orphan Drug Designation remains a central lever across major jurisdictions (FDA and EMA), and in the EU it provides development support and market exclusivity that has been used in HAE, including EMA orphan designations recorded in 2024 (EU/3/24/2898 in February 2024 and EU/3/24/2979 in November 2024).

Recent approvals point to regulator focus on reducing treatment burden through long-acting prophylaxis and oral options across broader age bands. In the United States, the FDA approved CSLs Andembry (garadacimab-gxii) in June 2025 as a prophylactic HAE treatment for patients aged 12 years and older, and the UK MHRA authorized KalVistas Ekterly (sebetralstat) in July 2025 for acute attacks in patients aged 12 years and older. In the EU, marketing authorizations such as Otsuka Pharmaceutical Netherlands B.V.'s Dawnzera (January 2026, for routine prevention of recurrent attacks in patients 12 years and older) reinforce a multi-region expansion pathway that increasingly depends on alignment mechanisms and structured post-authorization evidence generation.

Market Opportunities and Future Outlook

White space remains at the intersection of convenience and coverage gaps, especially on-demand oral therapy, pediatric formulations, and new prophylaxis mechanisms that reduce administration complexity versus intravenous or frequent injections. FDA approval of KalVistas Ekterly (sebetralstat) in July 2025 established an oral on-demand option for patients aged 12 years and older, supporting switching from injectable acute regimens and expanding treatment choices in markets with mature specialty distribution. In parallel, product-format innovation is also moving toward home use, including the EMA-approved pre-filled pen option for Takeda's Takhzyro (lanadelumab) in February 2025 for patients aged 12 years and older.

A second opportunity corridor is the pipeline-to-market transition for next-generation modalities and long-interval prophylaxis, which is already reflected in regulatory activity. In April 2026, Intellia initiated a rolling BLA submission to the FDA for lonvoguran ziclumeran (lonvo-z) as a one-time gene-editing treatment, and in July 2026 Pharvaris reported FDA acceptance of the NDA for deucrictibant immediate-release for on-demand treatment (with a PDUFA target action date of April 23, 2027). These steps highlight active development and review pathways that favor investments in manufacturing readiness, payer contracting infrastructure, and real-world evidence programs to support adoption across heterogeneous reimbursement systems, particularly outside Tier-1 academic centers where diagnostic and specialist capacity remains a constraint.